A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by activating the mother’s body’s defences to generate protective antibodies, which are then passed to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85% coverage when immunised 4 weeks before birth
- Antibodies from the mother passed through placenta safeguard newborns from day one
- Coverage possible with 2-week gap before early delivery
- Vaccination during third trimester still offers meaningful protection for infants
Strong evidence from the latest research
The performance of the pregnancy RSV vaccine has been established through a comprehensive study carried out throughout England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that six-month period, providing robust and representative data of the vaccine’s actual performance. The study’s findings have been supported by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scope of this study offers healthcare professionals and expectant parents with confidence in the vaccine’s demonstrated effectiveness across varied populations and settings.
The results reveal a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the great majority being infants whose mothers had not received the vaccination. This marked difference highlights the vaccine’s critical role in preventing serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospitalisations. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology measured real-world outcomes rather than experimental conditions, providing tangible evidence of how the vaccine functions when delivered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and its hazards
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed properly. Parents frequently observe their babies visibly struggling, their chests heaving as they try to pull enough air into their compromised lungs. Whilst most newborns get better with clinical support, a limited though important number die from RSV-related complications annually, making immunisation programmes a critical public health priority for protecting the youngest and most at-risk individuals in the population.
- RSV triggers lung inflammation, causing severe breathing difficulties in infants
- Nearly 50% of infants contract the virus during their first few months alive
- Symptoms span from mild colds to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK babies require serious hospital care for RSV annually
- Few infants succumb to RSV complications each year in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme commenced in 2024, health officials have emphasised the significance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that the timing is essential for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers nearly 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies transferred to their babies via the placenta.
The guidance from health authorities stays clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This flexible approach acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV represents the highest danger of serious illness.
Regional variations in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Certain regions have attained greater immunisation rates among eligible pregnant women, whilst others remain focused to increase awareness and access to the jab. These geographical variations demonstrate differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts launching diverse outreach initiatives to engage with women during pregnancy
- Inconsistencies across regions in vaccination coverage levels throughout England require targeted improvement
- Regional health providers modifying schemes to suit specific population needs
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness translates into concrete gains for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this protective measure, the 80% reduction in admissions represents thousands of infants spared from critical disease. Parents no longer face the distressing scenario of watching their newborns gasping for air or labour to feed, symptoms that characterise critical RSV illness. The vaccine has fundamentally shifted the picture of neonatal respiratory health, offering expectant mothers a preventative option to safeguard their most at-risk babies during those critical early months.
For families like that of Malachi, whose severe RSV infection caused devastating brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s advocacy for the jab underscores the life-altering consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to pregnant women during their third trimester, transforming what was once an unavoidable seasonal threat into a manageable health risk.